CN105287492A - Application of Mollanol A in preparation of medicines for treating cervical carcinoma - Google Patents
Application of Mollanol A in preparation of medicines for treating cervical carcinoma Download PDFInfo
- Publication number
- CN105287492A CN105287492A CN201510789615.1A CN201510789615A CN105287492A CN 105287492 A CN105287492 A CN 105287492A CN 201510789615 A CN201510789615 A CN 201510789615A CN 105287492 A CN105287492 A CN 105287492A
- Authority
- CN
- China
- Prior art keywords
- mollanol
- cervical carcinoma
- medicines
- preparation
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of Mollanol A in the preparation of medicines for treating cervical carcinoma and belongs to the technical field of new application of medicines. It is found through in vitro MTT antineoplastic activity evaluation that Mollanol A also has a remarkable inhibiting effect on growth of human cervical carcinoma cell lines HELA, HELA229, HCE1 and CASKI. Thus, Mollanol A can be used in the preparation of anti-cervical carcinoma medicines and has a good development and application prospect. The application of Mollanol A in the preparation of medicines for treating cervical carcinoma is disclosed for the first time. In addition, Mollanol A has an unexpectedly strong inhibitory activity to cervical carcinoma cells.
Description
Technical field
The present invention relates to the novelty teabag of compound MollanolA, particularly relate to the application of MollanolA in preparation treatment cervical cancer medicine.
Background technology
Cancer is to one of maximum disease of human life's health hazard, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.74% is had to be natural product or derivatives thereof in antitumor drug, if paclitaxel and derivant thereof are exactly the current reasonable antitumor drug of effect clinically.Therefore, from natural product, anticancer compound is found or lead compound has great importance.
The compound MollanolA that the present invention relates to is one and delivers (YongLi in 2014, etal., MollanolA, aDiterpenoidwithaNewC-Nor-D-homograyananeSkeletonfromthe FruitsofRhododendronmolle.OrganicLetters, 2014, 16, noval chemical compound 4320-4323.), this compound has brand-new framework types, there is sedation (YongLi, etal., MollanolA, aDiterpenoidwithaNewC-Nor-D-homograyananeSkeletonfromthe FruitsofRhododendronmolle.OrganicLetters, 2014, 16, 4320-4323.), the purposes of the MollanolA that the present invention relates in preparation treatment cervical cancer medicine is belonged to first public, owing to belonging to brand-new structure type, and its inhibit activities for cervical cancer cell is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control simultaneously for cervical cancer obviously has significant progress.
Summary of the invention
The object of the invention is to not find that it has the present situation of the report of anti-cervical cancer activity according in existing MollanolA research, provide MollanolA and preparing the application in medicament for resisting cervical cancer.
Described compound MollanolA, structure is as shown in formula I:
The present invention is found by external MTT antineoplastic activity evaluation, MollanolA also has significant inhibitory action to the growth of human cervical carcinoma cell lines HELA, HELA229, HCE1 and CASKI, suppresses the IC50 value of this 2 strain Growth of Cells to be respectively 4.89 ± 1.34 μMs, 4.76 ± 2.58 μMs, 5.70 ± 1.32 μMs and 4.79 ± 2.16 μMs.Therefore, MollanolA for the preparation of medicament for resisting cervical cancer, can have good development prospect.
The purposes of the MollanolA that the present invention relates in preparation treatment cervical cancer medicine is belonged to first public, because framework types belongs to brand-new framework types, and its inhibit activities for cervical cancer cell is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control simultaneously for cervical cancer obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The preparation method of compound MollanolA involved in the present invention is see document (YongLi, etal., MollanolA, aDiterpenoidwithaNewC-Nor-D-homograyananeSkeletonfromthe FruitsofRhododendronmolle.OrganicLetters, 2014,16,4320-4323.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound MollanolA tablet involved in the present invention:
Get 20 g of compound MollanolA, add the customary adjuvant 180 grams preparing tablet, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound MollanolA capsule involved in the present invention:
Get 20 g of compound MollanolA, add prepare capsule customary adjuvant as starch 180 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound MollanolA to the growth inhibited effect of human cervical carcinoma cell lines
1. method: the cell being in growth logarithmic (log) phase: human cervical carcinoma cell lines HELA, HELA229, HCE1 and CASKI (buying from Chinese Academy of Sciences's cell bank) are with 1.5 × 10
4concentration kind is in 96 orifice plates.Original culture medium is sucked after cell culture 24h is adherent.Test is divided into blank group, drug treating group.Blank group changes 1640 culture medium containing 10% hyclone; It is 100 μMs that drug treating group is changed containing concentration, 50 μMs, 10 μMs, 1 μM, 0.1 μM, the culture medium of the MollanolA of 0.01 μM and 0.001 μM.After cultivating 48h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator cultivates 4h, then 100 μ L supernatants are sucked along culture fluid top, add 100 μ LDMSO, 10min is placed in dark place, microplate reader (Sunrise Products) is utilized to measure light absorption value (wavelength 570nm), and calculating cell survival according to light absorption value, 6 repeating holes are established in each process.Cell survival rate (%)=Δ OD drug treating/Δ OD blank × 100.
2. the growth of result: MollanolA to human cervical carcinoma cell lines HELA, HELA229, HCE1 and CASKI has significant inhibitory action.This compound suppresses the IC50 value of human cervical carcinoma cell lines HELA, HELA229, HCE1 and CASKI growth to be respectively 4.89 ± 1.34 μMs, 4.76 ± 2.58 μMs, 5.70 ± 1.32 μMs and 4.79 ± 2.16 μMs.
Shown by above-described embodiment, the growth of MollanolA of the present invention to human cervical carcinoma cell lines HELA, HELA229, HCE1 and CASKI has good inhibitory action.Prove thus, MollanolA of the present invention has anti-cervical cancer activity, can for the preparation of medicament for resisting cervical cancer.
Claims (1)
- The application of 1.MollanolA in treatment cervical cancer medicine, described compound MollanolA structure is as shown in formula I:Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510789615.1A CN105287492A (en) | 2015-11-09 | 2015-11-09 | Application of Mollanol A in preparation of medicines for treating cervical carcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510789615.1A CN105287492A (en) | 2015-11-09 | 2015-11-09 | Application of Mollanol A in preparation of medicines for treating cervical carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105287492A true CN105287492A (en) | 2016-02-03 |
Family
ID=55185784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510789615.1A Pending CN105287492A (en) | 2015-11-09 | 2015-11-09 | Application of Mollanol A in preparation of medicines for treating cervical carcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105287492A (en) |
-
2015
- 2015-11-09 CN CN201510789615.1A patent/CN105287492A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105250250A (en) | Application of Nootkatone in preparation of medicine for treating nasopharyngeal carcinoma | |
| CN105267193A (en) | Application of Periconianone B to preparation of medicine for treating ovarian cancer | |
| CN105267221A (en) | Application of Norzoanthamine in preparation of drugs for treating prostate cancer | |
| CN105456243A (en) | Application of Flabelliferin B in preparing medicine for treating nasopharynx cancer | |
| CN105311026A (en) | Application of Leuconoxine in preparation of medicines for treating pancreatic cancer | |
| CN103479632B (en) | The application of Lycojaponicumin B in preparation treatment cervical cancer medicine | |
| CN103446092B (en) | The application of Incarviatone A in preparation treatment cervical cancer medicine | |
| CN103446147B (en) | The application of Lycojaponicumin C in preparation treatment cervical cancer medicine | |
| CN103463052B (en) | The application of Lycojaponicumin A in preparation treatment cervical cancer medicine | |
| CN103520175B (en) | The application of a kind of compound in preparation treatment cervical cancer medicine | |
| CN103446086B (en) | The application of Incarviatone A in preparation treatment gastric cancer medicament | |
| CN103446143B (en) | The application of Lycojaponicumin C in preparation treatment gastric cancer medicament | |
| CN103494812B (en) | The application of Lycojaponicumin A in preparation treatment ovarian cancer | |
| CN103463034B (en) | The application of Lycojaponicumin B in preparation treatment ovarian cancer | |
| CN103446091B (en) | The application of Incarviatone A in preparation treatment laryngeal carcinoma medicine | |
| CN105287492A (en) | Application of Mollanol A in preparation of medicines for treating cervical carcinoma | |
| CN103462969B (en) | The application of Incarviatone A in preparation treatment breast cancer medicines | |
| CN103446089B (en) | The application of Incarviatone A in preparation treatment medicine for nasopharyngeal | |
| CN103405421B (en) | Application of Chukrasone B in medicine for treating cervical cancer | |
| CN105287508A (en) | Use of Penifulvin A in preparation of drug for treating bladder cancer | |
| CN105395561A (en) | Application of Epishionol in preparation of drugs treating cervical cancer | |
| CN105497016A (en) | Application of Penicillactones A to preparation of drug for treating breast cancer | |
| CN105287530A (en) | Application of Zoanthamine in preparation of tongue cancer treating medicine | |
| CN105232524A (en) | Application of Rhodomollein XXV in preparation of skin cancer treatment medicine | |
| CN105232534A (en) | Application of Daphnilongeranin B in preparing drugs for treating ileocecum cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160203 |
|
| WD01 | Invention patent application deemed withdrawn after publication |